Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07300644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 24, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.
Trial Details
NCT Number NCT07300644
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions
(from sponsor)		 Pneumococcal Infectious Disease
Related terms Pneumococcal Infections
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov